Alcon Agrees to Acquire STAAR Surgical Company

Alcon Agrees to Acquire LENSAR, Inc.

March 24, 2025

Medical Devices

Alcon and LENSAR entered into a definitive merger agreement under which Alcon intends to acquire LENSAR for $14.00 per share in cash, plus a contingent value right that could add up to $2.75 per share. The total potential consideration is approximately $430 million, and the deal is expected to close in mid-to-late 2025 subject to customary approvals and LENSAR stockholder approval.

AbbVie Enters Strategic Alliance with iSTAR Medical for MINIject with Option to Acquire

July 20, 2022

Medical Devices

AbbVie has entered into a strategic alliance with iSTAR Medical to further develop and commercialize the MINIject minimally invasive glaucoma surgery (MIGS) device. iSTAR will receive a $60M non-dilutive upfront payment and AbbVie holds an exclusive right to acquire iSTAR, with up to $475M of additional contingent payments tied to closing and milestones; iSTAR will remain independent until completion of its STAR‑V study.

Alcon Acquires Aerie Pharmaceuticals, Inc.

August 22, 2022

Healthcare Services

Alcon entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, adding Rocklatan and Rhopressa commercial products along with AR-15512 and other ophthalmic pharmaceutical pipeline assets. The deal was funded with debt and was expected to close in Q4 2022, subject to customary approvals and conditions.

Alcon Acquires Ivantis, Inc.

January 10, 2022

Medical Devices

Alcon has completed its acquisition of Ivantis, Inc., the developer of the Hydrus Microstent, integrating Ivantis’ manufacturing and sales employees to expand Alcon’s global surgical ophthalmology portfolio. Alcon said it will leverage its global footprint to broaden Hydrus Microstent availability and continue clinical research, including pursuing stand‑alone surgery indications in the U.S.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Alcon Acquires Majority Interest in Aurion Biotech, Inc.

March 26, 2025

Biotechnology

Alcon has acquired a majority interest in clinical-stage Aurion Biotech to accelerate development and commercialization of Aurion's allogeneic corneal cell therapy AURN001. Aurion will remain a separate company while leveraging Alcon's global R&D, regulatory and commercial capabilities to advance AURN001 into U.S. Phase 3 development in the second half of 2025.